Manufactured Object

Biotech interest shifting from obesity ‘halo’ to other areas like oncology and blood cancers

1 day ago talkbio0Tagged Autoimmune, biotech pivot, Halo brace, Investments, leukemia, Neoplasms, Novartis, Obesity, sector rotation

obesity drugs; biotech pivot; investment trends; Novartis; leukemia; obesity halo; sector rotation; autoimmune; oncology

Tessera Therapeutics Strikes $150M Partnership with Regeneron for Gene Writing Therapy

1 week ago talkbio0Tagged alpha 1-Antitrypsin Deficiency, gene therapy, Gene Writing, Investments, Partnership, Regeneron, Tessera, TSRA-196

Tessera Therapeutics; Regeneron; gene writing; TSRA-196; AATD; alpha-1 antitrypsin deficiency; gene therapy; partnership; investment

MediView Achieves First CE Mark, Bringing Augmented Reality to European Healthcare

1 week ago talkbio0Tagged augmented, Augmented Reality, CE Mark, clinical visualization, European (ethnic group), GE HealthCare, Health care facility, Interventional radiology, MediView, MediView XR, MediView XR90, reality

MediView; CE Mark; augmented reality; European healthcare; mixed reality; clinical visualization; MediView XR; MediView XR90; GE Healthcare; interventional radiology

Rakovina Therapeutics Announces Q3 2025 Financial Results and Corporate Update

1 week ago talkbio0Tagged AI-powered, ATR Inhibitor, Clinical Nurse Specialists, Conferences, corporate milestones, development expenses, Ditiocarb, Drug Discovery, Eligibility Determination, financial results, Investments, NanoPalm joint-venture, net loss, Penetration, Q3, Rakovina, research

Rakovina Therapeutics; Q3 2025; financial results; net loss; research and development expenses; AI-powered drug discovery; ATR inhibitor; CNS penetration; corporate milestones; NanoPalm joint-venture; investment conference; DTC eligibility

Zentek Appoints Mohammed Jiwan as CEO

2 weeks ago talkbio0Tagged Appointments, CEO, commercialization, Graphene, Jiwan, Mohammed, Nanostructured Materials, Technology, ZenGUARD, Zentek

Zentek; Mohammed Jiwan; CEO appointment; ZenGUARD; nanomaterials; graphene; technology; commercialization

Novartis Announces Plans to Lay Off 550 Workers at Swiss Factory

2 weeks ago talkbio0Tagged Investments, layoffs, Novartis, pharmaceutical manufacturing, restructuring, Schweizerhalle, Stein facility, Switzerland

Novartis; layoffs; Switzerland; Stein facility; pharmaceutical manufacturing; restructuring; Schweizerhalle investment

AstraZeneca Onshores Rare Disease Portfolio as Part of $50B US Investment Pledge

2 weeks ago talkbio0Tagged AstraZeneca, expansion, Infrequent, Investments, Maryland (geographic location), onshoring, pledge, portfolio, R&D, U.S., Virginia facility

AstraZeneca; rare disease portfolio; onshoring; US investment; biomanufacturing; $50 billion pledge; Virginia facility; Maryland investment; R&D expansion

FDA Approves New Indication and Monthly Dosing for Regeneron’s Eylea HD

3 weeks ago talkbio0Tagged aflibercept, Approved, dosing, Eylea, Hodgkin Disease, Macular retinal edema, monthly, Ophthalmology specialty, Pre-filled Syringe, Regeneron, Retinal Diseases, Retinal Vein Occlusion, United States Food and Drug Administration

FDA approval; Eylea HD; Regeneron; macular edema; retinal vein occlusion; monthly dosing; ophthalmology; aflibercept; retinal diseases; pre-filled syringe

Scott Gottlieb, M.D., Joins UnitedHealth Group Board of Directors

3 weeks ago talkbio0Tagged board of directors, Health care facility, Health Policy, innovation, medical breakthroughs, Patient access, Scott Gottlieb, Technology, United States Food and Drug Administration, UnitedHealth Group

Scott Gottlieb; UnitedHealth Group; Board of Directors; FDA; health policy; innovation; patient access; medical breakthroughs; technology in healthcare

Eli Lilly to Acquire Adverum Biotechnologies in Gene Therapy Deal; Captain T Cell Secures €20M Funding

3 weeks ago talkbio0Tagged Acquisition, Adverum Biotechnologies, biotech, Captain T Cell, contingent value rights, CVR, eli lilly, financing characteristics, gene therapy, Investments, Ixo-vec, Ophthalmology specialty

Eli Lilly; Adverum Biotechnologies; Acquisition; Gene therapy; Ixo-vec; Contingent Value Rights (CVR); Ophthalmology; Captain T Cell; Financing; Biotech investment